AURKB and neoplasm: Upregulation of alternative kinases including aurora kinase B (AURKB), effect of tumor microenvironment on FLT3 clone sensitivity, and metabolic reprogramming have all been implicated as additional mechanisms resulting in early or late resistance to gilteritinib [42].